Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.21.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
OPERATING ACTIVITIES    
Net income (loss) $ 661 $ (418)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Provision for doubtful accounts (70) 285
Depreciation 2,527 2,328
Loss on disposal of and reserve adjustments for medical equipment 597 105
Loss (Gain) on sale of medical equipment 89 (1,140)
Amortization of intangible assets 1,043 1,075
Amortization of deferred debt issuance costs 96 4
Stock-based compensation 1,635 206
Deferred income taxes (180) 9
Changes in assets - (Increase)/Decrease:    
Accounts receivable (420) (1,628)
Inventories (154) (1,333)
Other current assets (244) (340)
Other assets (40) (19)
Changes in liabilities - (Decrease)/Increase:    
Accounts payable and other liabilities (2,889) 1,423
NET CASH PROVIDED BY OPERATING ACTIVITIES 2,651 557
INVESTING ACTIVITIES    
Acquisition of business (1,204) 0
Purchase of medical equipment (2,336) (4,007)
Purchase of property and equipment (138) (529)
Proceeds from sale of medical equipment, property and equipment 876 500
NET CASH USED IN INVESTING ACTIVITIES (2,802) (4,036)
FINANCING ACTIVITIES    
Principal payments on long-term debt (40,093) (9,229)
Cash proceeds from long-term debt 34,000 10,468
Debt issuance costs (386) 0
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans (565) (426)
Cash proceeds from stock plans 308 74
Common stock - issued 0 250
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES (6,736) 1,137
Net change in cash and cash equivalents (6,887) (2,342)
Cash and cash equivalents, beginning of period 9,648 2,647
Cash and cash equivalents, end of period $ 2,761 $ 305